Clinical Trials Logo

Recurrent Melanoma clinical trials

View clinical trials related to Recurrent Melanoma.

Filter by:

NCT ID: NCT00243061 Completed - Stage IV Melanoma Clinical Trials

AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

Start date: January 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well AZD2171 works in treating patients with recurrent or stage IV melanoma. AZD2171 may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00217542 Completed - Stage IV Melanoma Clinical Trials

Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery

Start date: July 2005
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of recombinant interferon alfa-2b when given together with azacitidine in treating patients with stage III or stage IV melanoma or stage IV kidney cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Recombinant interferon alfa-2b may interfere with the growth of tumor cells. Giving azacitidine together with recombinant interferon alfa-2b may kill more tumor cells.

NCT ID: NCT00121225 Completed - Stage IV Melanoma Clinical Trials

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

Start date: September 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well vorinostat works in treating patients with metastatic or unresectable melanoma. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00112476 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors

Start date: March 2005
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of temsirolimus when given together with bryostatin 1 in treating patients with unresectable or metastatic solid tumors. Drugs used in chemotherapy, such as temsirolimus and bryostatin 1, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

NCT ID: NCT00110019 Completed - Recurrent Melanoma Clinical Trials

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Start date: June 2005
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies carboplatin, paclitaxel, and sorafenib tosylate to see how well they work compared to carboplatin and paclitaxel in treating patients with stage III or stage IV melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether giving carboplatin and paclitaxel together with sorafenib tosylate is more effective than carboplatin and paclitaxel in treating melanoma.

NCT ID: NCT00101270 Completed - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas

Start date: March 2005
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of oxaliplatin when given together with irinotecan in treating young patients with refractory solid tumors or lymphomas. Drugs used in chemotherapy, such as oxaliplatin and irinotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Oxaliplatin may help irinotecan kill more cancer cells by making cancer cells more sensitive to the drug. Giving oxaliplatin together with irinotecan may kill more cancer cells.

NCT ID: NCT00089362 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors

Start date: July 2004
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of alvespimycin hydrochloride in treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy, such as alvespimycin hydrochloride, work in different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00085306 Completed - Stage IV Melanoma Clinical Trials

Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma

Start date: April 2004
Phase: Phase 2
Study type: Interventional

RATIONALE: Interferon beta may interfere with the growth of tumor cells. PURPOSE: This phase II trial is studying how well interferon beta works in treating patients with metastatic cutaneous (skin) melanoma or ocular (eye) melanoma.

NCT ID: NCT00085189 Completed - Stage IV Melanoma Clinical Trials

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Start date: May 2004
Phase: Phase 2
Study type: Interventional

This pilot phase II trial studies how well giving vaccine therapy works in treating patients with stage IIC-IV melanoma. Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to kill tumor cells

NCT ID: NCT00074308 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers

Start date: October 2003
Phase: Phase 1/Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of combining imatinib mesylate with bevacizumab in treating patients who have advanced melanoma or other metastatic or unresectable cancer. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Bevacizumab may stop the growth of tumor cells by stopping blood flow to the tumor. Combining imatinib mesylate with bevacizumab may kill more tumor cells